0NIQ.L - Sartorius Aktiengesellschaft

LSE - LSE Delayed Price. Currency in EUR
280.00
+4.03 (+1.46%)
As of 09:43AM BST. Market open.
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close275.97
Open278.50
Bid0.00 x 0
Ask0.00 x 0
Day's Range278.00 - 280.00
52 Week Range252.00 - 415.00
Volume72
Avg. Volume494
Market Cap199.761M
Beta (5Y Monthly)0.66
PE Ratio (TTM)0.44
EPS (TTM)6.35
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for 0NIQ.L

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • The Wall Street Journal

      Warburg Pincus Cashes Out of Polyplus in Lucrative Exit

      Warburg Pincus notched a hefty gain on its 2020 investment in gene-therapy technology company Polyplus-transfection SA, the latest in a string of healthcare transactions with big payoffs for the private-equity firm.

    • PR Newswire

      Sartorius with clear double-digit growth in fiscal 2022

      Following extraordinary growth in 2020 and 2021, the life science group Sartorius again outperformed the market in fiscal 2022, achieving its targets for sales revenue and profitability. Both divisions contributed to this development and, according to preliminary figures, recorded double-digit percentage growth in sales revenue and earnings year-over-year. For fiscal 2023, the company projects further growth and continued high profitability.

    • PR Newswire

      Sartorius with continued growth in a challenging environment

      The life science group Sartorius closed the first nine months of 2022 in both divisions with double-digit sales revenue and earnings growth and specified its outlook for the current fiscal year.

    • PR Newswire

      Sartorius to acquire Albumedix, strengthening its portfolio of innovative advanced therapy solutions

      The life science group Sartorius, through its French listed subgroup Sartorius Stedim Biotech, has agreed to acquire 100 percent of Albumedix Ltd. from private investors. The Nottingham, UK-based company provides best-in-class recombinant albumin-based solutions. Recombinant human albumin is an important component for the biopharmaceutical industry required for various applications, for example as an animal-free additive to cell culture media and for the stabilization of vaccines and viral thera